DTRA Archives - EverGlade Consulting

DTRA

DTRA’s “Plume” RFI for Marine Toxin Aerosol Exposure Models

Advancing Countermeasures for Marine Toxin Threats The Defense Threat Reduction Agency (DTRA), through its Research and Development Chemical and Biological Technologies Directorate in support of the Joint Science and Technology Office (JSTO), has issued a Request for Information (RFI) titled “Plume”. This initiative seeks information on the capabilities and availability of suitable animal models for […]

DTRA’s “Plume” RFI for Marine Toxin Aerosol Exposure Models Read More »

DTRA RAVEN Program

DTRA’s Reimagining the Next Generation of Biodefense Vaccines

Reimagining the Next Generation of Biodefense Vaccines: DTRA’s RAVEN Opportunity The Defense Threat Reduction Agency (DTRA), through its Joint Science and Technology Office (JSTO) and the Research and Development-Chem/Bio Medical Vaccines (RD-CBMV) division, has launched the Reimagining Available Vaccines and Envisioning Novelty (RAVEN) initiative. This forward-looking program is designed to modernize the nation’s medical countermeasure

DTRA’s Reimagining the Next Generation of Biodefense Vaccines Read More »

3d rendered image of highly pathogenic avian influenza

MCDC Announces “Increased Micro Sampling to Monitor Immunological Response” RPP

The Joint Science and Technology Office (JSTO) within the Defense Threat Reduction Agency (DTRA), has issued a new Request for Prototype Proposals (RPP) through the Medical CBRN Defense Consortium (MCDC). “Increased Micro Sampling to Monitor Immunological Response” (IMMIR) seeks to improve our ability to monitor immune responses to vaccination, which is critical for accelerating vaccine

MCDC Announces “Increased Micro Sampling to Monitor Immunological Response” RPP Read More »

digital rendering of antigens

MCDC Releases “Defined Rapid Antigen Identification and Immunogenic Characterization” RPP

The U.S. Department of Defense (DoD), through the Joint Science and Technology Office (JSTO) Defense Threat Reduction Agency (DTRA), has released a new Request for Prototype Proposals (RPP-25-07) under the Medical CBRN Defense Consortium (MCDC). This Request for Project Proposals, titled “Defined Rapid Antigen Identification and Immunogenic Characterization” (DRAIIC), aims to increase protection against infectious

MCDC Releases “Defined Rapid Antigen Identification and Immunogenic Characterization” RPP Read More »

Close-up of Medical Ampoule Production Line at Modern Modern Pharmaceutical Factory. Glass Ampoules are being Filled. Medication Manufacturing Process.

DTRA’s RAVEN RFI Seeks Multivalent Vaccine Innovation

Reimagining the Future of Vaccines: DTRA’s RAVEN RFI The Defense Threat Reduction Agency (DTRA), through its Joint Science and Technology Office (JSTO), has announced a new Request for Information (RFI) under the initiative titled Reimagining Available Vaccines and Envisioning Novelty (RAVEN). This RFI reflects DTRA’s responsibility to prepare the U.S. warfighter for current and emerging

DTRA’s RAVEN RFI Seeks Multivalent Vaccine Innovation Read More »

Chemical Threat Readiness

Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes

Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes April 2025 marks another pivotal moment for U.S. defense readiness in chemical and biological threat detection. Through the Medical CBRN Defense Consortium (MCDC), the Army Contracting Command has issued Solicitation RPP-25-04 seeking Enhanced White Papers for a groundbreaking prototype: the Assay Expansion for Chemical Diagnostic

Advancing Chemical Threat Readiness: The MCDC’s New Call for Prototypes Read More »

organophosphorus nerve agents

Project UPREG

Project UPREG: DTRA’s Push for Enhanced Protection Against Nerve Agents The Defense Threat Reduction Agency’s (DTRA) Chemical and Biological Technologies Department, in its role as the Joint Science and Technology Office (JSTO), has launched Project UPREG, a bold initiative to develop next-generation medical countermeasures against organophosphorus nerve agents (OPNAs). These highly toxic compounds pose a

Project UPREG Read More »

handheld diagnostic device

Assay Expansion for Chemical Diagnostic System

Assay-Expansion-for-Chemical-Diagnostics-System-SOO_Final The Defense Threat Reduction Agency’s Medical Diagnostics Branch (RD-CBMD) is driving innovation with its 2026 solicitation to expand the ChemDx platform. ChemDx is a handheld diagnostic device for rapid detection of chemical threats, such as nerve agents or certain pesticides, in blood from a finger prick. This effort seeks proposals from organizations interested in

Assay Expansion for Chemical Diagnostic System Read More »

technology to identify novel antigens

DTRA MCDC RAIIC Funding Opportunity

Final-draft-SOO-RAIIC The Joint Science and Technology Office (JSTO) Defense Threat Reduction Agency (DTRA) has announced an upcoming funding opportunity for members of the Medical CBRN Defense Consortium (MCDC) to develop technologies that can accelerate the identification and immune profile of novel antigens in emerging infectious diseases (EID). JSTO intends to incorporate the final technology into

DTRA MCDC RAIIC Funding Opportunity Read More »

compact wearable vaccine monitoring

DTRA Issues Draft SOO for Continual Blood Sampling Technology

Final-Draft-SOO-IMMIR The Joint Science and Technology Office (JSTO) within the Defense Threat Reduction Agency (DTRA) has announced an upcoming funding opportunity for members of the Medical CBRN Defense Consortium (MCDC). The objective of the IMMIR solicitation is to develop innovative technologies for vaccine monitoring via a compact wearable device that can analyze minute blood samples.

DTRA Issues Draft SOO for Continual Blood Sampling Technology Read More »

medical countermeasures

DTRA Issues SOO for Broad-Spectrum Therapeutics

August-24-Broad-Spectrum-SOO The Defense Threat Reduction Agency (DTRA) has released a Statement of Objectives (SOO) to develop  prototype Medical Countermeasures (MCMs) aimed at addressing therapeutic indications of Warfigher exposure to viral and bacterial biothreat agents. Key Information and Deadlines The Project Agreement Holder must state if their proposal is for the solution of the objecties of

DTRA Issues SOO for Broad-Spectrum Therapeutics Read More »

Female scientist in a hazmat suit researching WMD-related security challenges

DTRA BAA Weapons of Mass Destruction Amendment

DTRA BAA Outlines New Opportunity to Identify and Counter Weapons of Mass Destruction (WMD) through the Strategic Trends Research Initiative The Defense Threat Reduction Agency (DTRA) has amended its Broad Agency Announcement (BAA) to offer new funding opportunities through the Strategic Trends Research Initiative (STRI) for identifying and countering Weapons of Mass Destruction (WMD), defined

DTRA BAA Weapons of Mass Destruction Amendment Read More »

Scroll to Top